1-7 of 7
Mark C. Kelley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Rebecca L. Shattuck-Brandt, Sheau-Chiann Chen, Emily Murray, Christopher Andrew Johnson, Holly Crandall, Jamye F. O'Neal, Rami Nayef Al-Rohil, Caroline A. Nebhan, Vijaya Bharti, Kimberly B. Dahlman, Gregory D. Ayers, Chi Yan, Mark C. Kelley, Rondi M. Kauffmann, Mary Hooks, Ana Grau, Douglas B. Johnson, Anna E. Vilgelm, Ann Richmond
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3803–3818.
https://doi.org/10.1158/1078-0432.CCR-19-1895
Published: 15 July 2020
View articletitled, Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
Open the PDF for Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition in another window
Includes: Supplementary data
Journal Articles

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses

Jiqing Sai, Philip Owens, Sergey V. Novitskiy, Oriana E. Hawkins, Anna E. Vilgelm, Jinming Yang, Tammy Sobolik, Nicole Lavender, Andrew C. Johnson, Colt McClain, Gregory D. Ayers, Mark C. Kelley, Melinda Sanders, Ingrid A. Mayer, Harold L. Moses, Mark Boothby, Ann Richmond
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3371–3384.
https://doi.org/10.1158/1078-0432.CCR-16-2142
Published: 02 July 2017
View articletitled, PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Open the PDF for PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses in another window
Includes: Supplementary data
Journal Articles

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models

Yan Liu, Oriana E. Hawkins, Anna E. Vilgelm, Jeffrey S. Pawlikowski, Jeffrey A. Ecsedy, Jeffrey A. Sosman, Mark C. Kelley, Ann Richmond
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5338–5348.
https://doi.org/10.1158/1078-0432.CCR-15-0293
Published: 30 November 2015
View articletitled, Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Open the PDF for Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models in another window
Includes: Supplementary data
Journal Articles

RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

Yingjun Su, Anna E. Vilgelm, Mark C. Kelley, Oriana E. Hawkins, Yan Liu, Kelli L. Boyd, Sara Kantrow, Ryan C. Splittgerber, Sarah P. Short, Tammy Sobolik, Snjezana Zaja-Milatovic, Kimberly Brown Dahlman, Katayoun I. Amiri, Aixiang Jiang, Pengcheng Lu, Yu Shyr, Darrin D. Stuart, Shawn Levy, Jeffrey A. Sosman, Ann Richmond
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2184–2198.
https://doi.org/10.1158/1078-0432.CCR-11-1122
Published: 16 April 2012
View articletitled, RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Open the PDF for RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors in another window
Includes: Supplementary data
Journal Articles

Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation

Joshua A. Bauer, A. Bapsi Chakravarthy, Jennifer M. Rosenbluth, Deming Mi, Erin H. Seeley, Nara De Matos Granja-Ingram, Maria G. Olivares, Mark C. Kelley, Ingrid A. Mayer, Ingrid M. Meszoely, Julie A. Means-Powell, Kimberly N. Johnson, Chiaojung Jillian Tsai, Gregory D. Ayers, Melinda E. Sanders, Robert J. Schneider, Silvia C. Formenti, Richard M. Caprioli, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 681–690.
https://doi.org/10.1158/1078-0432.CCR-09-1091
Published: 14 January 2010
View articletitled, Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
Open the PDF for Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets

Yingjun Su, Katayoun I. Amiri, Linda W. Horton, Yingchun Yu, Gregory D. Ayers, Elizabeth Koehler, Mark C. Kelley, Igor Puzanov, Ann Richmond, Jeffrey A. Sosman
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 348–357.
https://doi.org/10.1158/1078-0432.CCR-09-2087
Published: 04 January 2010
View articletitled, A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets
Open the PDF for A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer

A. Bapsi Chakravarthy, Mark C. Kelley, Bernadette McLaren, Cristina I. Truica, Dean Billheimer, Ingrid A. Mayer, Ana M. Grau, David H. Johnson, Jean F. Simpson, R. Daniel Beauchamp, Catherine Jones, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1570–1576.
https://doi.org/10.1158/1078-0432.CCR-05-2304
Published: 06 March 2006
View articletitled, Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
Open the PDF for Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer in another window